Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Isoniazid Release from Suppositories Compounded with Selected Bases

Author(s):  Hudson Kristofer C, Asbill C Scott, Webster Andrew A

Issue:  Sep/Oct 2007 - Veterinary Compounding
View All Articles in Issue

Page(s):  433-437

Isoniazid Release from Suppositories Compounded with Selected Bases Page 1
Isoniazid Release from Suppositories Compounded with Selected Bases Page 2
Isoniazid Release from Suppositories Compounded with Selected Bases Page 3
Isoniazid Release from Suppositories Compounded with Selected Bases Page 4
Isoniazid Release from Suppositories Compounded with Selected Bases Page 5

Download in electronic PDF format for $75

Abstract:  There is an increasing need for an alternative route of isoniazid administration for prophylaxis and treatment of tuberculosis in children. The purpose of this study is to evaluate the in vitro release of isoniazid from extemporaneously compounded isoniazid suppositories with a goal of optimizing the suppository dosage form for this indication. Suppositories were compounded using three different base formulations (cocoa butter, Witepsol H15 Base F, and a combination of polyethylene glycols 3350, 1000, and 400). The release profiles of six compounded suppositories with isoniazid (100 mg) were tested with a United States Pharmacopeial Convention–approved dissolution apparatus. Isoniazid concentrations at predetermined time points were determined using high-performance liquid chromatographic analysis. The results show that drug release from the water-soluble base (mixed polyethylene glycols) was significantly greater than that from the lipophilic bases (cocoa butter and Witepsol H15). The percentage of isoniazid release from the polyethylene glycol suppository formulation (70 ± 1.4 mg/mL) was greater than that from the cocoa butter (55 ± 1.1 mg/mL) and Witepsol H15 Base F (18 ± 0.36 mg/mL) suppository formulations.

Related Keywords: Kristofer C. Hudson, PharmD, C. Scott Asbill, PhD, Andrew A. Webster, PhD, isoniazid, tuberculosis, rectal suppositories, intrarectal administration, prevention, children, cocoa butter, Witepsol H15 Base F, polyethylene glycol, formulations, excipients

Related Categories: EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, DOSAGE FORMS/DRUG CARRIERS, INFECTIOUS DISEASE, PREVENTIVE MEDICINE/WELLNESS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Isoniazid Release from Suppositories Compounded with Selected Bases
Hudson Kristofer C
, Asbill C Scott, Webster Andrew A
Sep/Oct 2007
Pg. 433-437

Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 10: Rectal Suppository Bases
Allen Loyd V Jr
Jul/Aug 2021
Pg. 304-309

Compounded Suppositories and Pharmaceutical Care
Duncan-Hewitt Wendy
, Rains John
Mar/Apr 1997
Pg. 93-99

Preparation and Evaluation of Sustained Drug Release from Pluronic Polyol Rectal Suppositories
Anderson Derick
, Amiji Mansoor M
May/Jun 2001
Pg. 234-237

Ketorolac tromethamine and Ketoprofen suppositories: release profiles and bioavailability of cocoa butter base formula in rabbits
Zia Hossein
, Rashed Suzette F, Quadir Mohammed, Needham Thomas E, Squillante Emilio
Sep/Oct 1998
Pg. 390-393

Basics: Hollow-type Suppositories
Allen Loyd V Jr
Jul/Aug 2022
Pg. 302-307

A New Proposal: Calculating Density Factors for Drugs Using Cocoa Butter as the Standard
Walker Heather
, Sridhar Vishak, Alexander Kenneth S
Nov/Dec 2011
Pg. 510-514

Enhanced Release of Diazepam from Hollow-Type Suppositories
Kaewnopparat N
, Kaewnopparat S, Rojanarat W, Ingkatawornwong S
Jul/Aug 2004
Pg. 310-312

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Isoniazid 300-mg Capsules
Allen Loyd V Jr
May/Jun 2013
Pg. 232

Rifampin 300-mg and Isoniazid 150-mg Capsules
Allen Loyd V Jr
Jul/Aug 2013
Pg. 334

Isoniazid 10 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Jan/Feb 2020
Pg. 58

Basics: Considerations and Background Information for Counseling Patients Using Compounded Suppositories
Allen Loyd V Jr
Jan/Feb 2022
Pg. 34-38

Isoniazid 10-mg/mL Oral Solution
Allen Loyd V Jr
Sep/Oct 2003
Pg. 376

Chemical Stability of Isoniazid in an Oral Liquid Dosage Form
Gupta Vishnu D
, Sood Arun
Mar/Apr 2005
Pg. 165-166

Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux through Rabbit Rectal Membrane
Tenjarla Srini N
, Ward Earl S, Fox Janet L
Jan/Feb 1998
Pg. 83-88

Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions
Polonini Hudson C
, Loures Sharlene, de Araujo Edson Peter, Brandão Marcos Antônio F, Ferreira Anderson O
Sep/Oct 2016
Pg. 426-434

Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)
Bakhteyar Hamid
, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
Sep/Oct 2017
Pg. 418-425

Comparing Suppository Mold Variability Which Can Lead to Dosage Errors for Suppositories Prepared with the Same or Different Molds
Alexander Kenneth S
, Baki Gabriella, Hart Christine, Hejduk Courtney, Chillas Stephanie
Nov/Dec 2013
Pg. 512-514

The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene
, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Jan/Feb 2014
Pg. 6-12

Return to Top